Cantor Fitzgerald Keeps Overweight on Agios Pharmaceuticals, Inc. (AGIO) Mar 2026

Cantor Fitzgerald on March 12, 2026 maintained an Overweight rating on Agios Pharmaceuticals, Inc. (AGIO). The headline AGIO analyst rating shows confidence in the company’s late‑stage program and commercial prospects. Cantor highlighted Aqvesme’s opportunity in thalassemia as a core reason to own the stock. We note the broker’s call coincided with a 0.36% intraday move, about $0.10, and a company market cap of $1,616,558,025. This piece breaks down the AGIO analyst rating, the firm’s rationale, and what investors should consider next.